BioNTechFull-Year Report 2023

Highlights

• Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024
• Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech’s strategy to develop combinatorial and synergistic therapeutic approaches
• Entered strategic collaborations with Biotheus, DualityBio, Medilink and OncoC4 to complement clinical oncology pipeline with innovative antibody-drug conjugate (ADC) and immuno-modulatory programs
• Annemarie Hanekamp appointed as Chief Commercial Officer effective July 1, 2024
• Delivered over 400 million COVID-19 vaccine doses worldwide in 2023, including successfully launched XBB.1.5 variant-adapted monovalent COVID-19 vaccine
• Progressed three infectious disease vaccine candidates into clinical evaluation, leveraging BioNTech’s mRNA technology and expertise
• Fourth quarter and full year 2023 revenues of €1.5 billion and €3.8 billion, respectively
• Full year net profit of €0.9billion and fully diluted earnings per share of €3.83 ($4.141)
• Strong financial position with €17.7 billion in cash, cash equivalents and security investments
• 2024 revenue guidance of €2.5 billion to €3.1 billion